Companion Animal Drugs Market Size By Product (Drugs {Antiparasitic, Anti-inflammatory, Anti-infectives, Corticosteroids, Tranquilizers, Cardiovascular Drugs, Gastrointestinal Drugs, Topical Glucocorticoids}, Vaccines {Modified Live Vaccines [MLV], Killed Inactivated Vaccines, Recombinant Vaccines}, Medicated Feed Additives {Antibiotics, Vitamins, Amino acids, Enzymes, Antioxidants, Prebiotics and Probiotics, Minerals, Carbohydrates, Propandiol}), By Animal Type (Dogs, Cats, Horses), By Route of Administration (Oral, Injectable, Topical), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacy and Drug Stores, E-commerce), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Mar 2021  |  Report ID: GMI4981  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 255   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Companion Animal Drugs Market size was valued at around USD 11.83 billion in 2020 and is projected to witness around 6% CAGR from 2021 to 2027. Rising adoption of pet animals due to growing urbanization and increase in number of nuclear families is among the primary market growth factors. Growing focus on animal health along with surging demand for pet insurance, especially in developed countries will augment the market expansion. The consistent rise in the number of diseases affecting animals is, in turn, generating demand for companion animal drugs. Additionally, the industrial growth is attributable to increasing incidence of zoonotic and food-borne diseases globally.
 

Companion Animal Drugs Market Overview

Get more details on this report - Request Free Sample PDF
 

Companion animal drugs include several drugs, vaccines and medicated feed additives that are used in diagnosis, mitigation and treatment of different animal diseases. Various diseases such as rabies, heartworm, cancer, kidney diseases, Lyme disease, among others in companion animals are treated using essential pharmaceutical products.
 

The emergence of COVID-19 has impacted several industrial sectors including companion animal healthcare. Animals including pet cats and dogs were reported with COVID-19 positive majorly in the initial period of crisis. According to the Centers for Disease Control and Prevention, some animals in zoological facilities tested positive for COVID-19 including large cats. Pets in close contact with people are supposed to be at higher risk of infection. Thus, prevalence of infection in these animals has escalated the R&D and demand for companion animal drugs. Government support to continue animal drug research during pandemic continued to sustain the industry growth.
 

Growing demand for online veterinary pharmacies will boost the companion animal drugs market value

Technological advances are reported in every sector including animal health, thereby driving the market progression. Increasing inclination towards mobile apps that help in tracking animal health habits, nutritional intake as well as alerts for pet care services will foster the market revenue. Most of the innovations in animal healthcare provide owners with pet cams and automated feeders that offer ease in pet care. The veterinary online pharmacies provide pet care products, supplements, vaccinations, injections, drugs and many more. High acceptance of e-commerce platforms in emerging economies assists in business revenue growth. Thus, integration of digital platforms in veterinary care and population preference shift towards online services will accelerate the overall market demand.
 

Increasing R&D activities related to vaccine development will spur the segment growth

 Vaccines segment accounted for more than USD 2.89 billion in 2020. Growing demand for new vaccines and medications for pets has resulted in increased spending on research and development activities for companion animal drugs. Owing to increased R&D, the market has witnessed emergence of new technologies including recombinant DNA vaccines for dogs in the companion animal drugs, thereby fuelling the industry expansion. This type of vaccine provides enhanced disease prevention to pet animals.
 

Wide acceptance and preference for dogs as a pet across the globe will drive the market growth

Dogs segment in the companion animal drugs market exceeded USD 4.76 billion in 2020. Increased pet adoption, especially in developed countries, has recorded surge in acceptance of dogs as companion animals. This can be primarily attributed to the fact that pets are known to reduce anxiety and stress levels in humans. Additionally, growing awareness among consumers regarding health and wellness of pets and maintaining proper hygiene at the pet’s place is supporting the demand for companion animal drugs.
 

Growing preference for oral route of administration will propel the market value

Oral segment size was around USD 2.86 billion in 2020 led by increasing preference of oral route of administration in companion animals. Various benefits associated with oral animal drugs such as reduced risk for acquiring infections, less pain, and requires no skin penetration support demand for oral dosage. Suspensions, solutions, capsules, as well as tablets forms of drugs, are administrated orally in companion animals to improve their health conditions and production.
 

Rising digitization coupled with consumer convenience will boost the e-commerce segment revenue

Companion Animal Drugs Market Size

Get more details on this report - Request Free Sample PDF
 

The companion animal drugs market for e-commerce distribution channel is anticipated to showcase a 6.8% growth rate by 2027. Numerous benefits associated with e-commerce such as the availability of medicines at discounted prices through online pharmacies, convenience for consumers, and growing digitization throughout the world are augmenting the market expansion. Moreover, companion animal drugs ordered through e-commerce facilitate a consistent supply of medication as they can be pre-ordered.
 

Increasing adoption of pets along with growing prevalence of animal disease in North America will impel the regional growth

Global Companion Animal Drugs Market

Get more details on this report - Request Free Sample PDF
 

In 2020, the U.S. companion animal drugs market dominated more than 88% of revenue share in the North America region owing to the consistent rise in the acceptance of pets in the country. According to the 2019- 2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 67 percent (or about 85 million) households in the U.S. owns a pet. Such high adoption rates coupled with supporting factors such as growing urbanization, rising awareness among consumers regarding pet's wellbeing are also fuelling the market revenue. Furthermore, availability of better health infrastructure, stringent regulatory guidelines for animal healthcare and increased spending on R&D initiatives are predicted to propel the companion animal drugs demand in the country.
 

The Brazil companion animal drugs market size was over USD 426 million in 2020. Brazil is among the leading countries in adoption of pet animals. This can be well understood from the fact that after Argentina and Mexico, Brazil is at third spot globally in terms of highest pet ownership. Thus, the high acceptance rate of pet animals is driving the industry value and is estimated to create lucrative opportunities in the coming period.
 

Presence of strong industry players implementing strategic initiatives will contribute to the market share

Boehringer Ingelheim, Symrise, Merck & Co, and Zoetis are some of the major companies operating in the market. Leaders are focusing on new product launches and adopting inorganic growth strategies to remain competitive and sustain in the market. Partnerships with other players enhance product offerings, thus helping the companies to increase their customer base by providing superior quality products.
 

Recent industry developments:

  • In Feb 2021, Vetoquinol acquired Canadian rights for the Profender product family from Elanco Animal Health. The acquisition is poised to impact company’s revenue and offer business development opportunities in untapped economies.
     
  • In Aug 2020, Elanco Animal Health Incorporated announced that it has acquired Bayer Animal Health. The transaction was valued at USD 6.89 billion. This development helped the company to expand itself in the durable animal health industry.
     

Companion animal drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:
 

Market, By Product, 2016 - 2027 (USD Million)

  • Drugs
    • Antiparasitic
    • Anti-inflammatory
    • Anti-infectives
    • Corticosteroids
    • Tranquilizers
    • Cardiovascular Drugs
    • Gastrointestinal Drugs
    • Topical Glucocorticoids
  • Vaccines
    • Modified Live Vaccines (MLV)
    • Killed Inactivated Vaccines
    • Recombinant Vaccines
  • Medicated Feed Additives
    • Antibiotics
    • Vitamins
    • Amino acids
    • Enzymes
    • Antioxidants
    • Prebiotics and probiotics
    • Minerals
    • Carbohydrates
    • Propandiol

Market, By Animals, 2016-2027 (USD Million)

  • Dogs
  • Cats
  • Horses
  • Others

Market, By Route of Administration, 2016-2027 (USD Million)

  • Oral
  • Injectable
  • Topical
  • Others

Market, By Distribution Channel, 2016-2027 (USD Million)

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacy and Drug Stores
  • E-commerce

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Poland
    • The Netherlands
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Taiwan
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Israel
       

Frequently Asked Questions (FAQ) :

The market revenue for companion animal drugs was recorded at nearly USD 11.83 billion in 2020 and will grow at a CAGR of about 6% through 2027.
The overall market share from the vaccines segment was valued at USD 2.89 billion in 2020 and will grow with soaring demand for novel medication and vaccines along with increasing R&D activities.
Oral segment accounted for nearly USD 2.86 billion in terms of revenue in 2020 and will expand owing to various benefits including less pain, decreased risk for infections as well as no skin penetration.
The e-commerce distribution channel will grow at a 6.8% rate through 2027 driven by its numerous benefits like discounts, convenience, and easy availability.
The U.S. captured over 88% of the North America companion animal drugs market share in 2020 and is poised to grow with the rising adoption of pets across the region.

Premium Report Details

  • Published Date: Mar 2021
  • Pages: 255
  • Tables: 457
  • Charts / Figures: 18
  • Companies covered: 9
  • Countries covered: 21

Get a report that explains COVID-19 impact on this market

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X